APL-509
/ JSR Life Sciences, Jiangsu Qyun Bio-Pharma, Apollomics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 04, 2019
A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.
(ASCO-SITC 2019)
- "Taken together, CBT-509 demonstrated an improvement over ipilimumab. Future efforts will focus on developing molecules that can further improve the efficacy and safety of anti-CTLA-4 based therapeutics."
Preclinical
February 26, 2019
A novel humanized anti-CTLA-4 antibody compared to ipilimumab in preclinical studies.
(ASCO-SITC 2019)
- "Taken together, CBT-509 demonstrated an improvement over ipilimumab. Future efforts will focus on developing molecules that can further improve the efficacy and safety of anti-CTLA-4 based therapeutics."
Preclinical
1 to 2
Of
2
Go to page
1